Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

In the present study, we investigate healthy subjects and schizophrenic patients who frequently show very low attentional capacity with functional magnetic resonance imaging (fMRI) and electrophysiology (EEG) during attention-requiring tasks to assess the level of attentional network activity.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Heinrich-Heine University, Duesseldorf
• Collaborator: German Research Foundation
• Treatments: Nicotine

Criteria

Inclusion Criteria:

• age 18-55

• informed consent

• negative drug-screening (cannabis, amphetamine, opiate, cocaine)

• no drug abuse in medical history for last 6 month

• no participation of subjects in other pharmacological trials within 6 weeks

• negative pregnancy test

• use of effective contraception within participation of trial

• normotonia (heart rate, RR)

• nicotine dependence (Fagerström >4)or not more than 20 cigarettes /lifetime

• nicotine (smoker serum > 2ng/mL)

• DSM-IV criteria for schizophrenia

• healthy subjects

Exclusion Criteria:

• known hypersensitivity towards nicotine or any substance of placebo preparation

• adenoids

• Rhinitis vaso.

• hypersensitivity of air passages

• cardiovascular diseases (defined)

• neurological diseases (defined)

• diabetes mellitus

• hyperthyreosis

• phaeochromocytoma

• Clozapine (schizophrenic)